Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M. Mitwasi N, et al. Among authors: rossig c. Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4. Sci Rep. 2020. PMID: 32034289 Free PMC article.
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Koristka S, Kegler A, Jureczek J, Hoffmann A, Ehninger A, Cartellieri M, Albert S, Rossig C, Ehninger G, Pietzsch J, Steinbach J, Bachmann M. Mitwasi N, et al. Among authors: rossig c. Oncotarget. 2017 Sep 18;8(65):108584-108603. doi: 10.18632/oncotarget.21017. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312553 Free PMC article.
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.
Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C. Kailayangiri S, et al. Among authors: rossig c. Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23. Mol Ther. 2019. PMID: 30879952 Free PMC article.
Redirecting T cells to treat solid pediatric cancers.
Rauwolf KK, Rossig C. Rauwolf KK, et al. Among authors: rossig c. Cancer Metastasis Rev. 2019 Dec;38(4):611-624. doi: 10.1007/s10555-019-09821-5. Cancer Metastasis Rev. 2019. PMID: 31811551 Review.
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.
Isfort I, Elges S, Cyra M, Berthold R, Renner M, Mechtersheimer G, Åman P, Larsson O, Ratner N, Hafner S, Simmet T, Schliemann C, Rossig C, Dirksen U, Grünewald I, Wardelmann E, Huss S, Hartmann W, Trautmann M. Isfort I, et al. Among authors: rossig c. Sci Rep. 2019 Dec 23;9(1):19704. doi: 10.1038/s41598-019-56247-8. Sci Rep. 2019. PMID: 31873172 Free PMC article.
Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Saleh HA, Mitwasi N, Ullrich M, Kubeil M, Toussaint M, Deuther-Conrad W, Neuber C, Arndt C, R Loureiro L, Kegler A, González Soto KE, Belter B, Rössig C, Pietzsch J, Frenz M, Bachmann M, Feldmann A. Saleh HA, et al. Among authors: rossig c. Front Immunol. 2023 Apr 14;14:1166169. doi: 10.3389/fimmu.2023.1166169. eCollection 2023. Front Immunol. 2023. PMID: 37122703 Free PMC article.
190 results